Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIM0618
- Development stage
- Unknown
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
SIM0618 is an investigational small molecule antagonist of the endothelin A receptor (ETAR) developed by Simcere Pharmaceutical (specifically through its oncology subsidiary, Simcere Zaiming). The endothelin system, particularly the ETAR signaling pathway, is known to play a critical role in tumor progression, including cell proliferation, survival, angiogenesis, and the development of bone metastases. By selectively antagonizing ETAR, SIM0618 aims to disrupt these oncogenic processes and inhibit tumor growth. It is currently being evaluated in early-stage clinical trials for the treatment of advanced solid tumors.
02
Targets
EDNRA (Endothelin receptor type A)
Beyond the preview
Go deeper on SIM0618.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIM0618.